Roche R&D Center China (RRDCC)

Media Visit to Roche in China

Shanghai 30 October 2005
Andreas Tschirky, Ph.D.
Head of Roche R&D Center (China) Ltd.
Roche recognizes changes in China

• Strong economic development over the last 20 years

• Reorganization of Healthcare System

(e.g. implementation of GCP and GLP in Hospitals,
re-organization of Chinese Pharmaceutical industry)

• Implementation of new laws

(e.g. intellectual property law and regulations)
•Re-organization of Academic institutions towards Centers of excellence
•Promotion of Hi-Technology (e.g. Bio-Technology)
• Shanghai: the Biotechnology hub of China
• Central and local government support innovation based industries
• Increasing number of highly educated Chinese (and returnees) in drug discovery
research
Shanghai and Pudong
The ZJ Pharma Valley

r
Contribute to ZJ - HiTech Park growth

ZhangJiang Pharma Valley

Shanghai Roche Pharmaceutical Ltd

Southern Genomics Center

Shiguang Hospital

Shanghai Institute of Materia Medica

Shanghai TCM University

Roche R&D Center (China) Ltd

Source: ZJ HiTech Park

China IPR

• Patent law established in 1985

• 1st Revision in 1992
– Expanded patent coverage to substance, formulation etc.
– Extended coverage time to 20 years
– Enforce the execution
• 2nd Revision in 2000
– Prepare for WTO
– Improved patent application, evaluation and approval process
– Strengthen patent enforcement
• China patent applications
– 85-04: 2.289 Mio, annual growth rate 18.9%
– 2004: 353 K
Roche R&D Center (China) Co. Ltd

• Owned by Roche
• Is a part of the Roche Global Research
• Located at Shanghai ZJHT Park
• Initially will be staffed with 40 scientists
• Conduct medicinal chemistry in lead generation
and optimization as a part of Roche Global Research
• Collaborate and create partnership in drug discovery
• Create and protect IP in China
• Strong co-operation with SRPL
Establishment of RRDCC
• Building infrastructure
• Research infrastructure
• Recruitment

Feb 04 Oct 04 Nov 04

Site Selected Site Opened Site Setup

Advertising… Hiring… Training

Jan 04 July 04 Dec 04
Site Announcement Site Construction Site Operation
Roche
R&D Collaboration Projects in China
Project Description Collaboration Partner

Schizophrenia related genes China Human Genome Center, Shanghai

Diabetes II/ Obesity related genes China Human Genome Center, Shanghai

Alzheimer’s disease related genes China Human Genome Center, Beijing

Diabetes II/ Obesity (Hypertension) China Human Genome Center, Beijing

Obesity / Hypertension Sino-German Genome Center, Beijing

Chronic Obstructive Pulmonary Disease Shanghai

Chemistry Outsourcing (Intermediates)Shanghai Institute of Organic Chemistry

Total Investment >4.5 million USD in the past few years

Outlook: RRDCC as Platform organization

Co-operation Communication with

Authorities and KOL
support functions RRDCC
(SRPL) In-house research
&
Joint projects
Training
&
Technology transfer
Outsourcing
& In-licensing support
Project management (IPR)

Roche is sending a very strong message to both the Chinese authorities and the scientific community
throughout the country that we share their vision of the future in which China will play an increasingly
important role in healthcare R&D
Potential new “Biotechnology valleys” in China

Hospitals
Major Pharmaceutical companies

Academic
Competence Centers
Investors
& (VC, Banks et al.)

Biotech Startups

Ref.: Boston, San Diego

Summary

• As a pioneer in Drug discovery among MNCs in China, Roche

understands itself as a reliable partner to Government, Academia
and Biotech industry.

•The creation of RRDCC represents a major long-term commitment to

China and reinforces the importance of China as a global player in
the field of biomedical science as and a growing market for our
healthcare products.

• Roche’s commitment is also based on confidence in China’s

embrace of WTO principles and responsible approach to intellectual
property protection.